ANDA 212206, held by Teva Pharms USA. Abiraterone Acetate.
As of Nov 15, 2026, ANDA 212206 (Abiraterone Acetate), held by Teva Pharms USA, was first approved by FDA on Jun 24, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 24, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Abiraterone Acetate125MG ยท tablet;oral | Abiraterone Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
